Quantifying concordant genetic effects of de novo mutations on multiple disorders
- Tsinghua University, China
- Yale University, United States
- Washington University in St. Louis, United States
- Rockefeller University, United States
- University of Wisconsin-Madison, United States
Abstract
Exome sequencing on tens of thousands of parent-proband trios has identified numerous deleterious de novo mutations (DNMs) and implicated risk genes for many disorders. Recent studies have suggested shared genes and pathways are enriched for DNMs across multiple disorders. However, existing analytic strategies only focus on genes that reach statistical significance for multiple disorders and require large trio samples in each study. As a result, these methods are not able to characterize the full landscape of genetic sharing due to polygenicity and incomplete penetrance. In this work, we introduce EncoreDNM, a novel statistical framework to quantify shared genetic effects between two disorders characterized by concordant enrichment of DNMs in the exome. EncoreDNM makes use of exome-wide, summary-level DNM data, including genes that do not reach statistical significance in single-disorder analysis, to evaluate the overall and annotation-partitioned genetic sharing between two disorders. Applying EncoreDNM to DNM data of nine disorders, we identified abundant pairwise enrichment correlations, especially in genes intolerant to pathogenic mutations and genes highly expressed in fetal tissues. These results suggest that EncoreDNM improves current analytic approaches and may have broad applications in DNM studies.
Data availability
The current manuscript is a computational study, so no data have been generated for this manuscript.
-
Evidence for 28 genetic disorders discovered by combining healthcare and research datahttps://doi.org/10.1038/s41586-020-2832-5.
-
Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autismhttps://doi.org/10.1016/j.cell.2019.12.036.
-
Exome sequencing in schizophrenia-affected parent-offspring trios reveals risk conferred by protein-coding de novo mutationshttps://doi.org/10.1038/s41593-019-0564-3.
-
Contribution of rare inherited and de novo variants in 2,871 congenital heart disease probandshttps://doi.org/10.1038/ng.3970.
-
Meta-analysis of 2,104 trios provides support for 10 new genes for intellectual disabilityhttps://doi.org/10.1038/nn.4352.
-
De Novo Coding Variants Are Strongly Associated with Tourette Disorderhttps://doi.org/10.1016/j.neuron.2017.04.024.
-
De novo mutations in epileptic encephalopathieshttps://doi.org/10.1038/nature12439.
-
Mutations disrupting neuritogenesis genes confer risk for cerebral palsyhttps://doi.org/10.1038/s41588-020-0695-1.
-
Exome sequencing implicates genetic disruption of prenatal neuro-gliogenesis in sporadic congenital hydrocephalushttps://doi.org/10.1038/s41591-020-1090-2.
-
Excess of rare, inherited truncating mutations in autismhttps://doi.org/10.1038/ng.3303.
Article and author information
Author details
Funding
National Science Foundation of China (No. 12071243)
- Lin Hou
Shanghai Municipal Science and Technology Major Project (No. 2017SHZDZX01)
- Lin Hou
Wisconsin Alumni Research Foundation
- Qiongshi Lu
Waisman Center pilot grant program at University of Wisconsin-Madison
- Qiongshi Lu
National Institutes of Health (No. R03HD100883 and R01GM134005)
- Hongyu Zhao
National Science Foundation (DMS 1902903)
- Hongyu Zhao
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Copyright
© 2022, Guo et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 986
- views
-
- 4
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Quantifying concordant genetic effects of de novo mutations on multiple disorders
eLife 11:e75551.
https://doi.org/10.7554/eLife.75551
Further reading
-
- Genetics and Genomics
Resistance to anthelmintics, particularly the macrocyclic lactone ivermectin (IVM), presents a substantial global challenge for parasite control. We found that the functional loss of an evolutionarily conserved E3 ubiquitin ligase, UBR-1, leads to IVM resistance in Caenorhabditis elegans. Multiple IVM-inhibiting activities, including viability, body size, pharyngeal pumping, and locomotion, were significantly ameliorated in various ubr-1 mutants. Interestingly, exogenous application of glutamate induces IVM resistance in wild-type animals. The sensitivity of all IVM-affected phenotypes of ubr-1 is restored by eliminating proteins associated with glutamate metabolism or signaling: GOT-1, a transaminase that converts aspartate to glutamate, and EAT-4, a vesicular glutamate transporter. We demonstrated that IVM-targeted GluCls (glutamate-gated chloride channels) are downregulated and that the IVM-mediated inhibition of serotonin-activated pharynx Ca2+ activity is diminished in ubr-1. Additionally, enhancing glutamate uptake in ubr-1 mutants through ceftriaxone completely restored their IVM sensitivity. Therefore, UBR-1 deficiency-mediated aberrant glutamate signaling leads to ivermectin resistance in C. elegans.
-
- Genetics and Genomics
Osteoporosis, characterized by reduced bone density and strength, increases fracture risk, pain, and limits mobility. Established therapies of parathyroid hormone (PTH) analogs effectively promote bone formation and reduce fractures in severe osteoporosis, but their use is limited by potential adverse effects. In the pursuit of safer osteoporosis treatments, we investigated R25CPTH, a PTH variant wherein the native arginine at position 25 is substituted by cysteine. These studies were prompted by our finding of high bone mineral density in a hypoparathyroidism patient with the R25C homozygous mutation, and we explored its effects on PTH type-1 receptor (PTH1R) signaling in cells and bone metabolism in mice. Our findings indicate that R25CPTH(1–84) forms dimers both intracellularly and extracellularly, and the synthetic dimeric peptide, R25CPTH(1–34), exhibits altered activity in PTH1R-mediated cyclic AMP (cAMP) response. Upon a single injection in mice, dimeric R25CPTH(1–34) induced acute calcemic and phosphaturic responses comparable to PTH(1–34). Furthermore, repeated daily injections increased calvarial bone thickness in intact mice and improved trabecular and cortical bone parameters in ovariectomized (OVX) mice, akin to PTH(1–34). The overall results reveal a capacity of a dimeric PTH peptide ligand to activate the PTH1R in vitro and in vivo as PTH, suggesting a potential path of therapeutic PTH analog development.
